DOCSLIB.ORG

Author Index Page Numbers in Italics Refer to Bibliography

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index Page Numbers in Italics Refer to Bibliography Author Index Page Numbers in italics refer to bibliography Aaron,T.H., Criep,L.H. 180. Adams,M.R., see Litchfield,J. Albert,A., Serjeant,E.P. 176, 207 T., Jr. 386, 409, 432, 441, 207 Aaron, T. H., see Criep, L. H. 465,496 Albert,J.R., see Lish,P.M. 398,427 Adamson,D.W., Barrett,P.A., 449, 465, 466, 495 Aarsen,P.N., Zeegers,A. 15, Billinghurst, J. W., Green, A. Albert, U., see Giertz, H. 444, 30 F .. Jones,T.S.G. 190,192, 489 Abbozzo, G., Genazzani, E., 207 Alberty,J. 387,425, 442, Donatelli, L. 562,570 Adamson, D. W., Barrett, P. A., 452--455,480 Abdel-Galil, A. A. M., Marshall, Billinghurst,J. W., Jones, T. Alberty, J., Huurrekorpi, L. P. B. 114, 122 S.G. 190,207 399, 425, 455, 480 Aborg, e.-H .. Novotny,J., Adamson, D. W., Billinghurst, Alberty,J., Schiede,M. 399, Uvniis,B. 86.90 J.W. 189,194,207 425,455,480 Aborg,e. H., Uvniis,B. 87, 90 Adashek, D., Grossman, M. I. Alberty, J., Takkunen, R. 467, Aborg, C.-H., see Uvniis,B. 58. 46,47,55 480 74. 75, 82, 84-87. 92 Adlerova, E., see Protiva, M. Albinus,M., Sewing.K.F. 2, Abram, L. E., see Cohen, M. B. 201, 212 3, 6, 8, 11, 21, 30, 264, 287, 421,427 Ado,A.D., Abrossimow,W.N. 463,480 Abrams,G., see Lear,E. 566, 453.480 Albrecht, I., see Cort, J. H. 579, 571 Ado, A. D., Ishimova, L. M., 597 Abramson, D. I.. Tuck, S .. Chu, Polner, A. A. 468,480 Aledort, L. M., see Goldman, B. L.S. W., Donatello, T. M. Agarwal, S. L., see Deshmanker, 543,556 22,30 B. S. 442, 486 Aleksandrowicz, D., see Traina, Abramson, D. I., Tuck. S .. Agrup, P., Granerus, G., Ja­ V. 442,502 Zayas, A. M., Donatello, cobsson, S., Wetterqvist, H., Alexander. F., Eyre,P., Head, T.M., Chu,L.S. W., Mit­ White, T. 142, 143 K. W., Sanford, J. 476.480 chell, R. E. 6,7,30 Ahlstrom,e.G., Johnston,M., Alexander, R. W., see Bush, J. E. Abrossimow, W. N., see Ado,A. Kahlson, G. 110, 122 378,379 D. 453,480 Ahmadi,A., Nemir,P., Jr., Alho,A.V., see Motsay,G.J. Abt, A. F., see Lamson, P. D. 3, Roth,J.L.A., Drabkin,D.L. 580,600 4,17,35 575,594 Al Katib, H., see Graham,J.D. Achenbach, P., Loew, E. R. Ahmed, A., Marshall, P. B. R. 322,331 463,480 303.329 Alksne, J. F. 423, 425 Ackermann,D. 381,425 Ahmed,A.E., see Hanna,P.E. Allan, G., see Levi, R. 1,35, Ackermann,D., Wasmuth, W. 204,206,210,240,247 443,460,495 369, 378, 381, 399, 405, 425, Aibara, S., see Ishida, Y. 375, Allen, G. S., Henderson, L. M., 442,455,480 377.379 Chou, S. N., French. L. A. Ackermann, H., Eichenberger, Aikawa, T., see Ishikawa, E. 27.30 E., Hunziker, F., Lauener, 111,125 Allen,J.E .. see Russo,R.M. H., Schmutz,J. 446,480 Ainsworth,e., Jones, R. G. 569,572 Adam,H.M., Hye,H.K.A. 286,287 Allen,L.E., see Lish,P.M. 568,570 Aitken, M. M., Sanford, J. 476, 449,465,466,495 Adam,H.M., Hye,H.K.A., 480 Waton,N.G. 114,122 Akabori, S., Kaneko, T. 286, Allinger, N. L., see Eliel, E. L. 271,289 Adamik,R., see Baxter,J.H. 287 66,69 Akagi,M., see Tasaka,K. 410, Allison,A.C.. see Orr. T. S. G. Adams,G.K., see Diamond,L. 436 59,72 410,428 Akcasu, A., West,G. B. 469, Allmark, M.G., see LU,F.e. Adams, H. R., see Goth, A. 63, 480 463,496 70, 100, 107 Akin,F.J., Tobia,A.J. 133, Allmark,M.G., see Stephen­ Adams, M. D., Hudgins, P. M. 134, 143 son, E. H. 561, 567, 572 23,30 Albert, A. 245 Alonso, L., see Litchfield, J. T., Adams,M.D., see Tobia,A.J. Albert, A., Goldacre, R., Phil­ Jr. 386,409,432,441, 465, 23,38 lips,J. 267,287 496 604 Author Index Alonso, M., see Fraile, A. 138, Altura, B. T., see Altura, B. M. Antonio,A., Funayama 312 145 1, 24-29, 31, 122, 123, 443, Antonio,A .. Rocha e Silva,M. Alonso-de-Florida, F., Castillo, 480, 508,510, 577-580, 584, 460,481 l.del, Garcia,X., Gijon,E. 589,593,595 Antonio, A., see Rocha e Silva, 456,480 Alworth,B.L., see Winbury,M. M. 317-319,332,435 Alonso-de-Florida, F., Castillo, M. 419,437 Appert, H. E., see Flynn, l. T. l.del, Gonzalez,C.C., San­ Amann,R., Werle,E. 83,90 584,598 chez,V. 456,480 Amann, R., see Werle, E. 83, Arbesman,e.E., Koepf,G.F., Alonso-de-Florida, F., Cordo­ 92 Lenzner,A.R. 421,425 ba, F. 455, 480 Ambache, N., Killick, S. W., Zar, Arbesman,C.E., Koepf,G.F., M.Aboo 440,456,481 Miller,G.E. 421,425,442, Alper,M.H., see Flacke, W. 7, Amundson,M.E., Manthey,l. 446,481 8, 11-15, 21, 34, 400, 429 A. 545,554 Arbesman, e. E., Neter, E., Alpers, H. S., see Geiger, W. B. Anan, S. 382,405,425 Becker,e.F. 468,481 455,488 Andem, M.R., see Haley, T.l. Arborelius, M., Lilja, B., Swen­ Alphin, R. S., see Lin, T. M. 121,124 son,E. W., Lindell, S. E., 252,253,291 Anders,M.W., see Hanna,P.E. Hjaltason, S. 16, 21, 32 Alten, P. 1. van, see Conway,A. 206,210 Arborelius, M., see Swenson, E. M. 478,485 Anderson, D. l., Emmlin, N. W. 16,21,38 Altu,G.K., see Clowes,G. HA. 390,416,425 Archer, G. T. 75, 78, 82, 90 lr. 575,597 Anderson, E. G., see Haas, H. L. Archer, R. K. 369, 375, 376, Altura,B.M. 1,23-28,30,31 568,571 378,378 Anderson,F. L., lubiz, W., Tsa­ Archer,R.K., Feldberg, W., Altura, B. M. 575, 577-582, jaris,T.l., Kuida,H. 584, Kovacs, B. A. 369, 372, 584-586,589,593,594,595 596 378 Altura,B.M., Altura,B.T. 1, Anderson,F.L., Kuida,H., Archibald,l.L., Benke,G.A. 24-29,31.122.123.443,480, Hecht,H.H. 5,15,17,31 207,207 508,510,577,578,580,584, Anderson, G. W., see Clapp, R. Archibald,l.L., Fairbrother,P., 589,593,595 C. 180,208,409,427 lackson,l.L. 206,207 Altura, B. M., Edgarian, H., Anderson, G. W., see Vaughan, Ariens,E.l. 215,217,245, Altura, B. T. 585, 595 l.R. 180,214 296, 301, 326, 327, 329, 345, Altura, B. M., Hershey, S. G. Anderson,M.M., see Winder, 352, 366 578, 579,595 e. V. 183, 214, 390, 409, Ariens, E. l., de Groot, W. M. Altura,B.M., Hershey,S.G., 413,416,437 333,366 Altura,B.T. 24,31,577, Anderson, M. W., Orton, T.e., Ariens,E.l., van Rossum,l.M., 579,595 Pickett, R. D., Eling, T. E. Koopman, P. 324, 329 Ariens,E.J., Simonis,A.M. Altura, B. M., Hershey, S. G., 547,554 254, 280, 285, 287, 296, 301, Mazzia, V. D. B. 577-580, Anderson, P., Slorach, S. A., 326,329,345,352,366 595 Uvnas,B. 59,69,79,90 Anderson, P., see Riihlich, P. Ariens, E. l., Simonis, A. M., Altura, B. M., Hershey, S. G., van Rossum,l.M. 252, Zweifach, B. W. 579,595 59, 73, 79, 91 Anderson,R.C., see Lee,H.M. 283,287,343,345,365,366 Altura, B. M., Hsu, R., Mazzia. 187,211,448,465,495 Ariens, E. l., see Ellenbroek, B. V.D.B., Hershey,S.G. Anderson, S. M., see Hansch, e. W. l. 352,366 579.595 262,290 Ariens, E. J., see Lehmann, P. A. Altura, B. M., Malaviya, D., Anderson, W., lr., see Maling, 352,366 Reich, C. F., Orkin, L. R. H. 508,510,511 Ariens, E. l., see Lien, E. l. 352, 27,28,31 Anderson, W., lr., see Webster, 367 Altura, B. M., Zweifach, B. W. M.E. 508,512 Ariens,E.l., see Simonis,A.M. 1, 23-25, 28, 31, 121, 123, Andersson,S., Uvnas,B. 80,90 352,365,367 462, 481, 575, 584, 585, 596 Andrako,l., see Stubbins,l.F. Arison, B. H., see Hucker, H. B. Altura, B. M., see Altura, B. T. 345,367 543-545,557 585,596 Andrews, P. R. 230, 245 Arison, B. H., see Porter, e. e. Altura, B. M., see Edgarian, H. Andrus, E. e., Wilcox, H. B., lr. 543,544,558 585,597 456,481 Armitage, P., Herxheimer, H., Altura, B. M., see Halevy, S. Andrus, E.e., see Wilcox, H. B., Rosa, L. 465,481 584, 592, 593, 598 lr. 456,503 Arnold, H., Brock, N., Kiihas, Angyal,S.J., see Eliel,E.L. E., Lorenz,D. 446, 465, Altura, B. M., see Hershey, S. G. 271, 289 481 577, 578, 579, 599 Ankier, S. 1. 474,481 Arnoldsson, H., see Liiwhagen, Altura, B. T., Altura, B. M. Anrep, G. V., Barsoum, G. S., O. 142, 147 585,596 Salama, S., Souidan, Z. Aronson,A.S. 456,481 Altura, B. T., Altura, B. M., 422,425 Arora,R.B., see Seth,S.D.S.
Load more

Recommended publications
  • Food and Drug Administration, HHS § 310.201
    Food and Drug Administration, HHS § 310.201 (d) Prescription legend not allowed on (v) The preparation is labeled with exempted drugs. The use of the prescrip- adequate directions for use in minor tion caution statement quoted in sec- conditions as a simple analgesic. tion 503(b) (4) of the act, in the labeling (vi) The dosages of N-acetyl-p-amino- of a drug exempted under the provi- phenol recommended or suggested in sions of this section, constitutes mis- the labeling do not exceed: For adults, branding. Any other statement or sug- 0.65 gram (10 grains) per dose or 2.6 gestion in the labeling of a drug ex- grams (40 grains) per 24-hour period: for empted under this section, that such children 6 to 12 years of age, one-half of drug is limited to prescription use, the maximum adult dose or dosage; for may constitute misbranding. children 3 to 6 years of age, one-fifth of (e) Prescription-exemption procedure of the maximum adult dose or dosage. OTC drug review. A drug limited to pre- (vii) The labeling bears, in juxtaposi- scription use under section 503(b)(1)(B) tion with the dosage recommendations, of the act may also be exempted from a clear warning statement against ad- prescription-dispensing requirements ministration of the drug to children by the procedure set forth in § 330.13 of under 3 years of age and against use of this chapter. the drug for more than 10 days, unless such uses are directed by a physician. [39 FR 11680, Mar.
    [Show full text]
  • Meeting Materials)
    California State Board of Pharmacy BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY 1625 N. Market Blvd, N219, Sacramento, CA 95834 DEPARTMENT OF CONSUMER AFFAIRS Phone: (916) 574-7900 GOVERNOR EDMUND G. BROWN JR. Fax: (916) 574-8618 www.pharmacy.ca.gov ENFORCEMENT AND COMPOUNDING COMMITTEE REPORT April 18, 2017 Amy Gutierrez, PharmD, Licensee Member, Chair Allen Schaad, Licensee Member, Vice Chair Greg Lippe, Public Member Stan Weisser, Licensee Member Valerie Muñoz, Public Member Ricardo Sanchez, Public Member I. Call to Order, Establishment of Quorum, and General Announcements II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings Note: The board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)] III. Enforcement Matters a. University of California, San Diego’s Pilot Program to Permit Patients to Access Medications from an Automated Drug Delivery System Not Immediately Adjacent to the Pharmacy Background At the April 2015 Board Meeting, the board approved an 18-month pilot study under the auspices of the University of California, San Diego (UCSD) School of Pharmacy involving use of an automated drug delivery system (ADDS) for prescription medication from which staff of Sharp Hospital in San Diego and their families, who opted in, could pick up their outpatient medications. Consultation would be provided via telephone before medication could be dispensed to a patient for first time fills. Since that time the committee has received quarterly updates on the study, including usage of the system.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • | Hao Ha Ta Maria Tai Mai Multe Detalian Mature
    |HAO HA TA MARIAUS009730892B2 TAI MAI MULTE DETALIAN MATURE (12 ) United States Patent ( 10 ) Patent No. : US 9 , 730 ,892 B2 Schutt et al. ( 45 ) Date of Patent : Aug . 15 , 2017 (54 ) METHOD FOR FORMULATING LARGE ( 56 ) References Cited DIAMETER SYNTHETIC MEMBRANE VESICLES U . S . PATENT DOCUMENTS 2 ,044 , 296 A 6 /1936 Hardgrove ( 71 ) Applicant : Pacira Pharmaceuticals , Inc ., San 2 ,824 ,807 A 2 / 1958 Laster et al . Diego , CA (US ) ( Continued ) (72 ) Inventors : Ernest George Schutt , San Diego , CA (US ) ; Ronald Warren McGuire , FOREIGN PATENT DOCUMENTS Murrieta , CA (US ) ; Peter Andrew AU 2002301268 B2 2 /2003 Walters, San Diego , CA (US ) ; AU 2006200044 Al 2 / 2006 Kathleen D . A . Los, San Diego , CA CA 933796 9 / 1973 ?? 960811 1 / 1975 (US ) CA 2 564 120 A1 8 / 1998 CA 2464668 5 / 2003 (73 ) Assignee : Pacira Pharmaceuticals , Inc ., San CH 519936 7 / 1971 Diego , CA (US ) CH 587023 7 / 1974 CN 101396345 5 / 2009 DE 1199191 8 / 1965 ( * ) Notice : Subject to any disclaimer, the term of this DE 51254 10 / 1966 patent is extended or adjusted under 35 DE 56223 5 / 1967 U . S . C . 154 ( b ) by 0 days . ( Continued ) ( 21 ) Appl . No . : 15 / 249 , 195 OTHER PUBLICATIONS Aug . 26 , 2016 (22 ) Filed : Atiemo -Obeng et al. “ Rotor - Stator Mixing Devices ” , Handbook of (65 ) Prior Publication Data Industrial Mixing Science and Practice , 2004 , 479 - 505 , Eds. Paul , US 2016 /0361260 A1 Dec . 15 , 2016 et al. , Hoboken , NJ: John Wiley and Sons , Inc. Related U . S . Application Data (Continued ) (63 ) Continuation of application No. 13 / 786 ,378 , filed on Primary Examiner — Monzer R Chorbaji Mar .
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Lack of Binding of Methapyrilene and Similar Antihistamines to Rat Liver DNA Examined by 32Ppostlabeling1
    [CANCER RESEARCH 48, 6475-6477, November 15, 1988| Lack of Binding of Methapyrilene and Similar Antihistamines to Rat Liver DNA Examined by 32PPostlabeling1 W. Lijinsky2 and K. Yamashita3 Biochemistry Division, National Cancer Center Research Institute, Tsukiji 5-chome, Chuo-ku, Tokyo, Japan ABSTRACT genie to bacteria (4) with rat liver activation and nonmutagenic to Drosophila," does not induce sister-chromatid exchange (5), The nonmutagenic carcinogen methapyrilene, together with several and has failed to transform mammalian cells in culture under noncarcinogenic analogues, was administered to rats p.o. for as long as 4 conditions in which many complex carcinogens are transform wk at concentrations of 0.1%. DNA was isolated from the liver and other ing (6). Methapyrilene is not highly toxic, and almost its only organs and hydrolyzed, and the identification of covalent adducts was made using the "P postlabeling method of Randerath. Some modified known biological action is to induce proliferation of mitochon procedures were also used to deal with the possibility of very mobile dria in rat liver (7), but not in the liver of hamsters or Guinea adducts being formed from these hydrophilic amines. Although the rats pigs (8). Methapyrilene has other effects on rat liver, which are had received as much as 2 g of amine per kg of body weight, no evidence difficult to relate to carcinogenesis, for example, increasing of formation of DNA adducts in liver or other organs was seen; the level lipid peroxidation (9); this property is shown equally, however, of detection was between 1 in 111"and 1 in 10' nucleotides.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • United States Patent (19) 11) Patent Number: 4,758,433 Johnson Et Al
    United States Patent (19) 11) Patent Number: 4,758,433 Johnson et al. (45. Date of Patent: Jul.19, 1988 54, OIL EXTRACT OF TANACETUM (56) References Cited PARTHENIUM FOR TREATING MIGRAINE PUBLICATIONS El-Ferally et al., Chem. 89: 87138k. 75) Inventors: Edward S. Johnson, Maidenhead; Joshi, Chem. Abst. 86: 72888u. Peter J. Hylands; Deborah M. Edriguez et al., 86: 72889y. Hylands nee Jessup, both of Picman et al., Chem. Abs. 100:99724g. Hausen et al., Chem. Abs. 100: 1884.5 x. Wickham, all of England Djermanovic et al., Chem. Abst. 97: 212667a. Mladenovic et al., Chen. Abst. 97: 212668b. (73) Assignee: R. P. Scherer Corp., Troy, Mich. Bohlmann et al., Chem. Abst. 97: 1594.79n. Stevens, Chem. Abst. 97: 159480t. 21 Appl. No.: 749,008 Hladon et al., Chem. Abst. 91: 68299p. Ogura et al., Chem. Abst. 90: 23285u. Lee et al., Cancer Research 31, 1649-1654, Nov. 1971. 22 Filed: Jun. 26, 1985 Soucek et al., Collective Czech. Chem. Comm., 1961, vol. 26, pp. 803-809. Blakeman, Chem. Abst. 91: 2076.14c. Related U.S. Application Data Romo et al., Tetrahedron, 1965, vol. 21, pp. 1744-1745. 63 Continuation-in-part of Ser. No. 494,964, May 16, Hall et al., Journal of Pharmaceutical Sciences, vol. 68, 1983, abandoned. No. 5, May 1979. Primary Examiner-Jane T. Fan (30) Foreign Application Priority Data Attorney, Agent, or Firm-Omri M. Behr May 19, 1982 (GB) United Kingdom ................. 82.14572 (57 ABSTRACT Sep. 22, 1982 GB United Kingdom ................. 8227062 A preparation for pharmaceutical use, especially in the treatment of migraine, arthritis and bronchial com 51) Int.
    [Show full text]
  • United States Patent (10) Patent No.: US 9,492,541 B2 Srinivasan Et Al
    USOO9492541 B2 (12) United States Patent (10) Patent No.: US 9,492,541 B2 Srinivasan et al. (45) Date of Patent: *Nov. 15, 2016 (54) PHENYLEPHERINE CONTAINING DOSAGE 4,839,354 A * 6/1989 Sunshine et al. .......... 514,226.5 FORM 4,882,158 A 11/1989 Yang et al. 5,032,401 A 7, 1991 Jamas et al. 5,133,974 A 7, 1992 Paradissis et al. (75) Inventors: Viswanathan Srinivasan, The 5,445,829 A 8, 1995 Paradissis et al. Woodlands, TX (US); Ralph Brown, 5,840,731 A * 11/1998 Mayer et al. ................. 514,289 Southlake, TX (US); David Brown, 6,001,392 A * 12/1999 Wen et al. .................... 424/486 Colleyville, TX (US); Juan Carlos 3:52,- 4 R 358, Stiling et al. Menendez, Bedford, TX (US); 6,462,094 B1 10/2002 Dang et al. Venkatesh Balasubramanian, 6,602,521 B1 8/2003 Ting et al. Arlington, TX (US); Somphet Peter 6,699,502 B1 3/2004 Fanara et al. Suphasawud, Fort Worth, TX (US) 6,797.283 B1 9, 2004 Edgren et al. 2004/022O153 A1 11/2004 Jost-Price et al. 2004/0229849 A1 11/2004 Jost-Price et al. (73) Assignee: SOVEREIGN 2004/0253311 A1 12/2004 Berlin et al. PHARMACEUTICALS, LLC, Fort 2005/0112199 A1 5.2005 Padval et al. Worth, TX (US) 2005/O152967 A1 7/2005 Tengler et al. 2005/O153947 A1 7/2005 Padval et al. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 2648 days.
    [Show full text]